Monogenic obesity; using drugs to bypass the problem
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Safe and effective pharmacological treatments for severe obesity remain scarce. In this issue, Iepsen et al. show that obese patients with pathogenic melanocortin 4 receptor mutations, the most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) receptor agonist therapy.
Description
Journal Title
Cell Metabolism
Conference Name
Journal ISSN
1550-4131
1932-7420
1932-7420
Volume Title
28
Publisher
Elsevier
Publisher DOI
Rights and licensing
Except where otherwised noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Sponsorship
Medical Research Council (MC_UU_12012/1)
Medical Research Council (MC_UU_12012/5)
Medical Research Council (MC_PC_12012)
Medical Research Council (MC_UU_12012/5)
Medical Research Council (MC_PC_12012)
A.P.C. is supported by the Medical Research Council (MRC Metabolic Diseases Unit [MRC_MC_UU_12012/1]).